Premium
An ApoA‐I Mimetic Peptide High‐Density‐Lipoprotein‐Based MRI Contrast Agent for Atherosclerotic Plaque Composition Detection
Author(s) -
Cormode David P.,
BrileySaebo Karen C.,
Mulder Willem J. M.,
Aguinaldo Juan Gilberto S.,
Barazza Alessandra,
Ma Yanqing,
Fisher Edward A.,
Fayad Zahi A.
Publication year - 2008
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.200701285
Subject(s) - confocal , lipoprotein , contrast (vision) , confocal microscopy , cholesterol , nanoparticle , chemistry , pathology , medicine , materials science , nanotechnology , biochemistry , biology , microbiology and biotechnology , computer science , geometry , mathematics , artificial intelligence
Cardiovascular disease is one of the prime causes of mortality throughout the world and there is a need for targeted and effective contrast agents to allow noninvasive imaging of the cholesterol‐rich atherosclerotic plaques in arteries. A new, fully synthetic, high‐density lipoprotein (HDL)‐mimicking MRI contrast agent is developed, which enhances macrophage‐rich areas of plaque in a mouse model of atherosclerosis by 94%. Confirmation of the targeting of this nanoparticulate agent is achieved using confocal microscopy by tracking a fluorescent lipid incorporated into the nanoparticle.